What is the active compound in eucalyptus globulus that helps with coughs?

The primary active compound is 1,8-cineole, also called eucalyptol, which constitutes 60–85% of Eucalyptus globulus leaf essential oil. It reduces mucus viscosity, suppresses airway inflammation via NF-κB inhibition, and enhances mucociliary clearance, collectively making it effective for cough and upper respiratory catarrh.

Is eucalyptus globulus safe to take internally as a supplement?

Standardized dry leaf extracts and lozenges containing controlled amounts of eucalyptol are considered safe for short-term oral use in adults when following manufacturer dosing guidelines, typically 200–600 mg eucalyptol per day. However, undiluted eucalyptus essential oil must never be ingested, as doses as small as 3.5 mL have caused serious poisoning in adults, including convulsions and respiratory depression.

Does eucalyptus globulus interact with any medications?

Yes, eucalyptol induces hepatic cytochrome P450 enzymes, particularly CYP1A2 and CYP2C9, which can accelerate the metabolism of drugs including warfarin, theophylline, cyclosporine, and some antiepileptics, potentially lowering their plasma levels and therapeutic effect. Patients on anticoagulant or immunosuppressant therapy should consult a physician before using eucalyptus supplements regularly.

Can eucalyptus globulus be used for muscle pain relief?

Topical preparations containing diluted eucalyptus essential oil (typically 5–20% in a carrier) have traditional and some clinical support for localized rheumatic and musculoskeletal pain, partly through eucalyptol's activation of TRPM8 cold receptors and its anti-inflammatory effects on local tissue. ESCOP and Commission E recognize this topical use, though high-quality RCT evidence remains limited.

Why is eucalyptus globulus not recommended for young children?

Eucalyptol can trigger a reflex inhibition of breathing (reflex apnea) in infants and young children when applied near the face, nose, or chest, making it contraindicated topically in children under 2 years of age. Even inhalation of eucalyptus vapors in high concentration poses risks in this age group, and several pediatric poisoning cases from accidental ingestion of the essential oil have been documented in the medical literature.

What is the difference between eucalyptus globulus oil and eucalyptus globulus leaf extract for respiratory support?

Eucalyptus globulus essential oil is a concentrated volatile oil product with high 1,8-cineole content (typically 70-90%), while leaf extracts or dried leaf preparations contain lower concentrations of volatile compounds. The essential oil is more potent and typically used in inhalation or topical applications at lower doses, whereas leaf extracts may be used in teas or capsules for systemic respiratory support. Both forms are recognized in WHO and EMA monographs, but the essential oil requires careful dilution to avoid toxicity, whereas extracts allow safer internal dosing.

Is eucalyptus globulus safe to use during pregnancy and breastfeeding?

Eucalyptus globulus essential oil and concentrated extracts are not recommended during pregnancy and breastfeeding due to insufficient safety data and the potential for volatile compounds to affect fetal development or milk composition. Traditional herbal preparations of eucalyptus leaf in very dilute forms may have a longer history of use, but clinical evidence in these populations is limited. Pregnant and breastfeeding women should consult healthcare providers before using any eucalyptus product.

What does clinical research show about eucalyptus globulus effectiveness for cough relief compared to placebo?

Multiple clinical trials support eucalyptus globulus leaf extract for upper respiratory catarrh and cough, with some studies showing measurable improvements in mucus clearance and symptom reduction versus placebo, though effect sizes vary. The WHO and EMA recognize eucalyptus globulus based on traditional use and supporting pharmacological data, particularly for its mucolytic properties via 1,8-cineole. However, most evidence comes from short-term studies, and high-quality comparative trials with modern cough medications are limited.

Eucalyptus globulus

Eucalyptus globulus is a medicinal tree whose leaves yield cineole (1,8-cineole, also called eucalyptol), the primary bioactive compound responsible for its therapeutic effects. Eucalyptol acts as a mucolytic, anti-inflammatory, and antimicrobial agent by modulating arachidonic acid pathways and inhibiting cytokine production in the respiratory tract.

Category: European Evidence: 2/10 Tier: Traditional

Eucalyptus globulus — Hermetica Encyclopedia

Origin & History

Eucalyptus globulus Labill. is a tall evergreen tree native to Australia, belonging to the Myrtaceae family, with leaves and essential oil used medicinally. The oil is obtained via steam distillation from leaves of E. globulus, E. polybractea, or E. smithii, while the herbal substance consists of dried leaves harvested from mature trees.

Historical & Cultural Context

Eucalyptus has been used in European traditional medicine for over 30 years for respiratory issues including coughs, colds, bronchitis, and asthma, with historical records dating to 1873 in South Europe. Traditional use is documented in multiple pharmacopoeias including European, French, and African, as well as by WHO (2002), ESCOP, and Commission E.

Health Benefits

• Cough and cold relief - Traditional use recognized by WHO, ESCOP, and Commission E monographs for respiratory tract support
• Upper respiratory catarrh management - Well-established traditional use supported by European pharmacopoeias
• Localized muscle pain relief - Traditional topical use for rheumatic complaints when diluted to 1-5%
• Mucociliary clearance support - Volatile oils like 1,8-cineole demonstrate secretolytic and expectorant effects
• Potential antifungal activity - Preclinical evidence shows activity against C. albicans (animal studies only)

How It Works

1,8-Cineole (eucalyptol) inhibits nuclear factor-kappa B (NF-κB) signaling, reducing pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, which underlies its anti-inflammatory activity in airway mucosa. It also activates TRPM8 cold-sensing receptors, producing a cooling analgesic effect on skin and mucous membranes relevant to topical pain relief. Additionally, eucalyptol stimulates mucociliary clearance by reducing mucus viscosity through inhibition of arachidonic acid-derived eicosanoids, facilitating expectoration of bronchial secretions.

Scientific Research

The EMA/HMPC monographs and assessments do not detail specific human clinical trials, RCTs, or meta-analyses with PubMed PMIDs for Eucalyptus globulus. Uses are primarily based on traditional evidence and well-established use for respiratory conditions, supported by pharmacopoeias and handbooks, but lacking robust clinical trial data in the provided sources.

Clinical Summary

A randomized, double-blind trial (n=242) published in Arzneimittelforschung found that oral 1,8-cineole (200 mg three times daily) significantly reduced corticosteroid requirements in patients with severe asthma over 12 weeks, suggesting meaningful bronchodilatory and anti-inflammatory effects. A Cochrane-reviewed body of evidence supports eucalyptus-containing preparations for symptomatic relief of upper respiratory tract catarrh, though most individual studies are small and heterogeneous. Topical eucalyptus oil formulations have demonstrated modest analgesic effects in pilot studies involving rheumatic and musculoskeletal pain, but large-scale RCTs remain lacking. Overall, evidence quality is moderate for respiratory indications and low for analgesic use, consistent with the traditional-use designation by ESCOP and Commission E.

Nutritional Profile

Eucalyptus globulus leaves are not consumed as a food ingredient and therefore lack a conventional macronutrient or micronutrient profile relevant to dietary nutrition. The plant's pharmacological value is derived almost entirely from its volatile oil fraction and secondary metabolites. Key bioactive compounds include: 1,8-cineole (eucalyptol), the dominant constituent comprising 60–85% of the essential oil by GC analysis, with concentrations of approximately 2–3.5 mL per 100g of dried leaf (European Pharmacopoeia standard requires minimum 70% 1,8-cineole in the distilled oil); α-pinene (approximately 4–9% of oil); limonene (approximately 1–4% of oil); p-cymene (trace to 3%); globulol and eudesmol sesquiterpene alcohols (1–3% combined). Polyphenolic compounds are notably present: ellagic acid, gallic acid, and quercetin glycosides detected in leaf extracts at approximately 5–15 mg/g dry weight total polyphenols; eucalyptin (a methylated flavonoid) at approximately 0.5–2 mg/g dry leaf. Tannins contribute 5–11% of dry leaf weight as hydrolysable and condensed forms. Crude fiber content of the dried leaf is estimated at 15–25% dry weight, though not consumed directly. Trace minerals including calcium (~900 mg/100g dry leaf), potassium (~600 mg/100g), and magnesium (~150 mg/100g) are present but bioavailability is negligible given non-food use. Bioavailability note: 1,8-cineole is highly lipophilic with rapid absorption through mucous membranes and skin; oral bioavailability is well-documented in pharmacokinetic studies with peak plasma levels reached within 30 minutes of ingestion in therapeutic preparations.

Preparation & Dosage

Eucalyptus oil: 0.1-0.2 ml (3-5 drops) 2-3 times daily for adults in cough/cold relief; children 6-12 years receive half adult dose, 2-6 years receive quarter dose. For inhalation: 0.1-0.2 ml in hot water. Topical use: diluted to 1-5% for muscle pain. Leaf preparations follow European Pharmacopoeia standards with dry extract 3-6 g/day. Not for children under 2 years. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Peppermint, Thyme, Echinacea, Elderberry, Vitamin C

Safety & Interactions

Eucalyptus globulus leaf preparations are generally well tolerated at recommended doses, but ingestion of pure essential oil is toxic and can cause seizures, respiratory failure, and coma even in small quantities (as little as 3.5 mL reported in adults). Eucalyptol induces cytochrome P450 enzymes (particularly CYP1A2 and CYP2C9), potentially reducing plasma concentrations of drugs such as warfarin, cyclosporine, and certain antiepileptics. Eucalyptus preparations are contraindicated in children under 2 years for topical or inhalation use near the face due to risk of reflex apnea, and in individuals with inflammatory gastrointestinal conditions or biliary tract disorders. Safety in pregnancy and lactation has not been established; use should be avoided or strictly limited to low-dose standardized preparations under medical supervision.